<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03430232</url>
  </required_header>
  <id_info>
    <org_study_id>STR-324-CL-039</org_study_id>
    <secondary_id>2014-002402-21</secondary_id>
    <nct_id>NCT03430232</nct_id>
  </id_info>
  <brief_title>First-In-Human PainCart Study for STR-324</brief_title>
  <official_title>A First-in-Human, Randomized, Double-blind, Placebo-controlled Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of STR-324 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stragen France</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stragen France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an interventional, first-in-man study, double-blind, placebo-controlled, two-part,
      ascending doses study to investigate the safety, tolerability and efficacy of STR-324
      infusions in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part I : ascending doses of short lasting infusion Part II : ascending doses of long lasting
      infusion
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2018</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>For part I: crossover model For part II: parallel model</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability: number of subjects who experience (serious) treatment emergent adverse events, potential clinically changes in vital signs, ECG, holter, physical examinations, laboratory tests and urine production</measure>
    <time_frame>Day 7 (+/- 2 days) post dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parts I and II: Maximum plasma concentration (Cmax)</measure>
    <time_frame>Up to 24 hours for Part I and up to 56 hours for Part II</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts I and II:Time to maximum plasma concentration (Tmax)</measure>
    <time_frame>Up to 24 hours for Part I and up to 56 hours for Part II</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts I and II: Area under the plasma concentration-time curve from zero to infinity(AUC0-inf)</measure>
    <time_frame>Up to 24 hours for Part I and up to 56 hours for Part II</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts I and II: Area under the plasma concentration-time curve from zero to the last measured concentration above the limit of quantification (AUC0-last)</measure>
    <time_frame>Up to 24 hours for Part I and up to 56 hours for Part II</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts I and II: Terminal disposition rate constant (λz) with the respective half-life (t½)</measure>
    <time_frame>Up to 24 hours for Part I and up to 56 hours for Part II</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts I and II: Amount excreted in urine in 24 hours</measure>
    <time_frame>Up to 24 hours for Part I and up to 56 hours for Part II</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts I and II: Thermal Pain</measure>
    <time_frame>Up to 5 hours for part I and up to 56 hours for part II</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts I and II: Electrical pain Stair and Burst</measure>
    <time_frame>Up to 5 hours for part I and up to 56 hours for part II</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts I and II: Pressure Pain</measure>
    <time_frame>Up to 5 hours for part I and up to 56 hours for part II</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts I and II: Cold Pressor</measure>
    <time_frame>Up to 5 hours for part I and up to 56 hours for part II</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts I and II: Conditioned Pain Modulation Response (change from electrical stair pre- and post-cold pressor)</measure>
    <time_frame>Up to 5 hours for part I and up to 56 hours for part II</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts I and II: Visual Analogue Scale Bond &amp; Lader</measure>
    <time_frame>Up to 5 hours for part I and up to 56 hours for part II</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts I and II: Visual Analogue Scale Bowdle</measure>
    <time_frame>Up to 5 hours for part I and up to 56 hours for part II</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II only: Saccadic eye movement</measure>
    <time_frame>Up to 56 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II only: Smooth pursuit eye movement</measure>
    <time_frame>Up to 56 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II only: Adaptive tracking</measure>
    <time_frame>Up to 56 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II only: Body sway</measure>
    <time_frame>Up to 56 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II only: N-Back</measure>
    <time_frame>Up to 56 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II only: Pharmaco-EEG: power</measure>
    <time_frame>Up to 56 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II only: Pupillometry</measure>
    <time_frame>Up to 56 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II only: 49-item Addiction Center Research Inventory</measure>
    <time_frame>Up to 60 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II only: Bowel Function Index</measure>
    <time_frame>Up to day 7</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Part I (Panel 1): STR-324 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive STR-324 dose level 1, 3, 5, 7 or placebo as a short infusion according to randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part I (Panel 2): STR-324 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive STR-324 dose level 2, 4, 6, 8 or placebo as a short infusion according to randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II (Panel 1): STR-324 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive STR-324 dose level A or placebo as a long infusion according to randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II (Panel 2): STR-324 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive STR-324 dose level B or placebo as a long infusion according to randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II (Panel 3): STR-324 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive STR-324 dose level C or placebo as a long infusion according to randomization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Short infusion of the solution for intravenous administration, Sodium Chloride 0.9%</description>
    <arm_group_label>Part I (Panel 1): STR-324 or placebo</arm_group_label>
    <arm_group_label>Part I (Panel 2): STR-324 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STR-324 Dose Level 1</intervention_name>
    <description>Short infusion of a solution for intravenous administration</description>
    <arm_group_label>Part I (Panel 1): STR-324 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STR-324 Dose Level 2</intervention_name>
    <description>Short infusion of a solution for intravenous administration</description>
    <arm_group_label>Part I (Panel 2): STR-324 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STR-324 Dose Level 3</intervention_name>
    <description>Short infusion of a solution for intravenous administration</description>
    <arm_group_label>Part I (Panel 1): STR-324 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STR-324 Dose Level 4</intervention_name>
    <description>Short infusion of a solution for intravenous administration</description>
    <arm_group_label>Part I (Panel 2): STR-324 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STR-324 Dose Level 5</intervention_name>
    <description>Short infusion of a solution for intravenous administration</description>
    <arm_group_label>Part I (Panel 1): STR-324 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STR-324 Dose Level 6</intervention_name>
    <description>Short infusion of a solution for intravenous administration</description>
    <arm_group_label>Part I (Panel 2): STR-324 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STR-324 Dose Level 7</intervention_name>
    <description>Short infusion of a solution for intravenous administration</description>
    <arm_group_label>Part I (Panel 1): STR-324 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STR-324 Dose Level 8</intervention_name>
    <description>Short infusion of a solution for intravenous administration</description>
    <arm_group_label>Part I (Panel 2): STR-324 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STR-324 Dose Level A</intervention_name>
    <description>Long infusion of a solution for intravenous administration</description>
    <arm_group_label>Part II (Panel 1): STR-324 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STR-324 Dose Level B</intervention_name>
    <description>Long infusion of a solution for intravenous administration</description>
    <arm_group_label>Part II (Panel 2): STR-324 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STR-324 Dose Level C</intervention_name>
    <description>Long infusion of a solution for intravenous administration</description>
    <arm_group_label>Part II (Panel 3): STR-324 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Long infusion of the solution for intravenous administration, Sodium Chloride 0.9%</description>
    <arm_group_label>Part II (Panel 1): STR-324 or placebo</arm_group_label>
    <arm_group_label>Part II (Panel 2): STR-324 or placebo</arm_group_label>
    <arm_group_label>Part II (Panel 3): STR-324 or placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent prior to any study-mandated procedure

          -  Healthy male subjects, 18 to 45 years of age, inclusive at screening.

          -  Body mass index (BMI) between 18 and 30 kg/m2, inclusive at screening, and with a
             minimum weight of 50 kg.

          -  All males must practice effective contraception during the study and be willing and
             able to continue contraception for at least 90 days after their last dose of study
             treatment.

          -  Has the ability to communicate well with the Investigator in the Dutch language and
             willing to comply with the study restrictions.

        Exclusion Criteria:

          -  Evidence of any active or chronic disease or condition that could interfere with, or
             for which the treatment of might interfere with, the conduct of the study, or that
             would pose an unacceptable risk to the subject in the opinion of the investigator

          -  Subject with clinically significant abnormalities in blood pressure, heart rate, ECG
             recording and laboratory parameters

          -  Abnormal renal function (eGFR (MDRD) &lt; 60 mL/min/1.73m2).

          -  Previous history of seizures or epilepsy.

          -  Acute disease state (e.g. nausea, vomiting, fever, or diarrhea) within 7 days before
             the first study day.

          -  Positive Hepatitis B surface antigen (HBsAg), Hepatitis B antibodies, Hepatitis C
             antibody (HCV Ab), or human immunodeficiency virus antibody (HIV Ab)

          -  Use of any medications (prescription or over-the-counter [OTC]), within 14 days of
             study drug administration, or less than 5 half-lives (whichever is longer).

          -  Use of any vitamin, mineral, herbal, and dietary supplements within 7 days of study
             drug administration, or less than 5 half-lives (whichever is longer).

          -  Participation in an investigational drug or device study within 3 months prior to
             first dosing.

          -  History of abuse of addictive substances or current use of substances (alcohol,
             illegal substances)

          -  Positive test for drugs of abuse or alcohol breath test at screening or pre-dose.

          -  Any confirmed significant allergic reactions (urticaria or anaphylaxis) against any
             drug, or multiple drug allergies (non-active hay fever is acceptable).

          -  Loss or donation of blood over 500 mL within three months prior to screening

          -  Any current, clinically significant, known medical condition in particular any
             existing conditions that would affect sensitivity to cold or pain
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Annie-Claude Benichou, MD</last_name>
    <phone>+33 478 42 95 26</phone>
    <email>ac.benichou@stragen.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHDR</name>
      <address>
        <city>Leiden</city>
        <zip>2333</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geert Jan Groeneveld, MD</last_name>
      <phone>+31 71 5246 400</phone>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2018</study_first_submitted>
  <study_first_submitted_qc>February 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2018</study_first_posted>
  <last_update_submitted>February 23, 2018</last_update_submitted>
  <last_update_submitted_qc>February 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

